Lyell Immunopharma, Inc. (LYEL) stock forecast & analysis
15.00
NasdaqGS · USDDelayed by 15 minutes
Down: -0.43, -2.8%
15.00Unchanged: +0.00, +0.0%
1 analysis
Latest analysis: · verdict locked
- Open
- 15.05
- Previous close
- 15.43
- Day range
- 14.18 – 16.20
- 52-week range
- 7.20 – 45.00
- Volume (shares)
- 634.83K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 24.51M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- -0.09
- Market cap
- 367.58M
Market Scanner’s AI analysis of Lyell Immunopharma, Inc. (LYEL), updated November 2026: Lyell Immunopharma's Ronde-Cel program advances with private placement and upcoming data presentations
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Lyell Immunopharma, Inc. (LYEL) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Lyell Immunopharma's Ronde-Cel program advances with private placement and upcoming data presentations
Recent analyses for Lyell Immunopharma (LYEL) covered its Q3 earnings and business highlights, including financial results and progress on its Ronde-Cel program. The company secured an $80 million private placement to support its Biologics License Application (BLA) submission for Ronde-Cel. Updates on clinical trials and manufacturing transfers were also noted.
LYEL news & sentiment
Market and social media sentiment around Lyell Immunopharma (LYEL) appeared positive, driven by news of an $80 million private placement and promising clinical trial updates for its Ronde-Cel program. Discussions highlighted upcoming data presentations and progress on manufacturing transfers, contributing to a generally favorable outlook.
LYEL technical picture
The stock LYEL has experienced a significant upward trend over the past 30 days, trading well above its 50-day SMA but below its 200-day SMA. Short-term momentum indicators such as the 10-day EMA, RSI, MFI, and MACD all confirmed positive momentum, with RSI and MFI readings suggesting potential overvaluation due to strong buying pressure.
Fundamentals
Lyell Immunopharma reported substantial cash reserves with a strong current and quick ratio, alongside significant debt. The company experienced a steep year-over-year quarterly revenue decline and negative trailing twelve months revenue, with deeply negative operating margins and return on equity. Annual and quarterly net losses were substantial, indicating a consistent pattern of negative profitability.
Factors discussed — upside
- Stock price increased 70.1% over the past 30 days.
- Price trading 42.2% above its 50-day SMA.
- Positive short-term momentum indicated by 10-day EMA.
- High RSI and MFI suggest strong buying pressure.
- Positive MACD confirms bullish momentum.
Factors discussed — risks
- Stock price trading below its 200-day SMA, indicating a long-term downtrend.
- RSI above 70 suggests the stock may be overvalued in the short term.
- Year-over-year quarterly revenue growth of -50%.
- Significant net losses reported annually and quarterly.
- Operating Margin TTM of -704,307.4%.
- Clinical trial progress
- Financing activities
- Technical indicators
- Financial performance
Summary updated .
LYEL technical indicators
Common technical indicators for LYEL, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 10.85 | Price above |
| 10-day exponential moving average | 11.94 | Price above |
| Relative strength index (14-day) | 75.83 | Overbought |
| MACD line (12/26/9) | 0.8412 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 5.91 – 14.12 | Price above the upper band |
Analyses
Recent LYEL.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-05 LYEL.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Lyell Immunopharma, Inc.?
- The bull case discussed centers on significant recent price momentum, with the stock experiencing a substantial upward trend and trading well above its 50-day simple moving average. Positive short-term indicators, including the 10-day EMA, high RSI and MFI suggesting strong buying pressure, and a positive MACD, further support this outlook.
- What are the risks for Lyell Immunopharma, Inc.?
- The bear case highlights that the stock is trading below its 200-day SMA, indicating a long-term downtrend, and that current high RSI levels may suggest it is overvalued in the short term. Additionally, analyses noted a significant year-over-year quarterly revenue decline and substantial net losses with a highly negative operating margin.
- Is Lyell Immunopharma, Inc. bullish or bearish?
- Recent AI analyses of Lyell Immunopharma, Inc. examined factors on both sides. Discussed upside: The bull case discussed centers on significant recent price momentum, with the stock experiencing a substantial upward trend and trading well above its 50-day simple moving average. Positive short-term indicators, including the 10-day EMA, high RSI and MFI suggesting strong buying pressure, and a positive MACD, further support this outlook. Discussed risks: The bear case highlights that the stock is trading below its 200-day SMA, indicating a long-term downtrend, and that current high RSI levels may suggest it is overvalued in the short term. Additionally, analyses noted a significant year-over-year quarterly revenue decline and substantial net losses with a highly negative operating margin. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Lyell Immunopharma, Inc.?
- Market and social media sentiment around Lyell Immunopharma (LYEL) appeared positive, driven by news of an $80 million private placement and promising clinical trial updates for its Ronde-Cel program. Discussions highlighted upcoming data presentations and progress on manufacturing transfers, contributing to a generally favorable outlook.
- How does Market Scanner analyse Lyell Immunopharma, Inc.?
- Every analysis of Lyell Immunopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Lyell Immunopharma, Inc.?
The bull case discussed centers on significant recent price momentum, with the stock experiencing a substantial upward trend and trading well above its 50-day simple moving average. Positive short-term indicators, including the 10-day EMA, high RSI and MFI suggesting strong buying pressure, and a positive MACD, further support this outlook.
What are the risks for Lyell Immunopharma, Inc.?
The bear case highlights that the stock is trading below its 200-day SMA, indicating a long-term downtrend, and that current high RSI levels may suggest it is overvalued in the short term. Additionally, analyses noted a significant year-over-year quarterly revenue decline and substantial net losses with a highly negative operating margin.
Is Lyell Immunopharma, Inc. bullish or bearish?
Recent AI analyses of Lyell Immunopharma, Inc. examined factors on both sides. Discussed upside: The bull case discussed centers on significant recent price momentum, with the stock experiencing a substantial upward trend and trading well above its 50-day simple moving average. Positive short-term indicators, including the 10-day EMA, high RSI and MFI suggesting strong buying pressure, and a positive MACD, further support this outlook. Discussed risks: The bear case highlights that the stock is trading below its 200-day SMA, indicating a long-term downtrend, and that current high RSI levels may suggest it is overvalued in the short term. Additionally, analyses noted a significant year-over-year quarterly revenue decline and substantial net losses with a highly negative operating margin. These are descriptive observations, not a recommendation.
What is the latest sentiment on Lyell Immunopharma, Inc.?
Market and social media sentiment around Lyell Immunopharma (LYEL) appeared positive, driven by news of an $80 million private placement and promising clinical trial updates for its Ronde-Cel program. Discussions highlighted upcoming data presentations and progress on manufacturing transfers, contributing to a generally favorable outlook.
How does Market Scanner analyse Lyell Immunopharma, Inc.?
Every analysis of Lyell Immunopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh LYEL.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.